PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Proteomics. Author manuscript; available in PMC 2010 June 3.
Published in final edited form as:
Curr Proteomics. 2010 April 1; 7(1): 49–65.
PMCID: PMC2880513
NIHMSID: NIHMS205683

DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER

Abstract

Lung cancer is the leading cause of cancer death for both men and women in the United States, and similar trends are seen world wide. The lack of early diagnosis is one of the primary reasons for the high mortality rate. A number of biomarkers have been evaluated in lung cancer patients, however, their specificity and early stage diagnostic values are limited. Using traditional protein chemistry and proteomics tool we have demonstrated higher serum haptoglobin levels in small cell lung cancer (SCLC). Similar findings have been reported for other cancers including ovarian cancer and glioblastoma. Haptoglobin is an acute phase protein with at least six possible phenotypes. The six phenotypes, in combination with two post translational modifications, glycosylation and deamidation, lead to large numbers of possible haptoglobin isoforms. Recent studies indicate a possible correlation between specific haptoglobin glycosylation and particular disease conditions. In our current study, we have fractionated control and SCLC patient serum by 2-D gel electrophoresis to identify differentially expressed haptoglobin isoforms in SCLC serum samples.

Keywords: Serum, Haptoglobin, Isoforms, Small cell lung cancer

Introduction

Lung cancer is the most common cause of cancer death world wide, with over one million cases annually (WHO, economics of tobacco control). For 2009, it is predicted that 219,440 new cases of lung cancer will be diagnosed in the United States, 15% of which are small cell lung cancer (SCLC) and the rest non-small cell lung cancer (NSCLC) [1]. [1]. The overall survival for patients with SCLC is quite poor. Approximately 1/3 of patients initially present with limited disease (LD, within the chest cavity) their survival rate is only 20–25% over 5 years. A majority of SCLC patients present with extensive disease (ED, metastatic) and their chances of survival is less than 5% over 5 years. The methods of detecting early SCLC are poor and better strategies are urgently needed. Serum biomarkers for lung cancer have been studied in the hope of achieving early detection of the disease, improving diagnosis, predicting response or monitoring recurrence after treatment [2]. Nonetheless, their present clinical usefulness remains limited [3,4]. CEA, α-1-acid glycoprotein (AGP), neuron-specific enolase (NSE), chromogranin A (ChrA), bombesin-like gastrin-releasing peptide (GRP), and BB isoenzyme of creatine kinase (CK-BB) are some of the candidate serum biomarker for SCLC [5]. Many potentially useful candidates continue to be tested, especially serum cytokines. These include vascular endothelial growth factor (VEGF), stem cell factor (SCF) and hepatocyte growth factor/scatter factor (HGF/SF) [32]. However the clinical applications of all these serum biomarkers are limited.

Haptoglobin is an acute phase protein and has been reported to be indicative of various pathological conditions including diverse forms of cancer, cirrhosis of the liver, and hepatitis-C [68]. It binds to hemoglobin and is a marker for hemolysis [9]. Haptoglobin has also been shown to inhibit prostaglandin synthesis and angiogenesis and it constitutes about 0.4–2.6% of total serum protein [10,11]. Native haptoglobin is a heterotetramer composed of two α and two β subunits attached by disulfide bridges [12]. The human β subunit is a 38 kDa polypeptide linked to α isoforms by a disulfide bridge. There is only one type of β subunit, while the α chain is represented by two isoforms α-1 and α-2. The amino acid sequences in α isoforms are similar, with the α-1 isoform having 83 amino acids (9-kDa polypeptide). The α-2 isoform is a duplicate of the α-1 chain, with a repeat insert of amino acid residues 12 to 70, thus the α-2 chain has 142 amino acids (20 kDa polypeptide). One of the distinct features of distinct feature of β-haptoglobin is its high level of glycosylation. The β-haptoglobin chain has 243 amino acids, with a molecular mass of more than 40 kDa. It is estimated that the β chain contains approximately 30% carbohydrate moiety [13,14].

We have reported a higher circulatory level of α haptoglobin in SCLC patients. Our studies also indicated a possible correlation between the disease state and the level of α-haptoglobin in serum [15]. The present study is an extension of our earlier work In this study we have analyzed serum and haptoglobin enriched serum fractions to determine the differential expression of specific haptoglobin isoforms in SCLC patient serum. The samples were analyzed by two dimensional gel electrophoresis (2D-GE) and sodium dodecyll sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE). Once fractionated, the proteins were characterized either by immunoblotting or silver stain in combination with mass spectrometry. The present study confirms our earlier findings that higher serum levels of α and β haptoglobin isoforms were observed in SCLC patient samples. Also, we have demonstrated a β chain variant (5 kDa smaller than the full length) differentially expressed in SCLC patient serum.

Materials and methods

Serum Sample Collection

Serum from control or SCLC patients were collected as described earlier (4), with institutional review board (IRB) approved informed consent.

Serum haptoglobin enrichment by albumin and immunoglobulin depletion

To remove albumin, the method developed by Colantonio et. al was followed with modifications [16]. Briefly, serum samples of 100 to 500 µl were incubated with 0.1 M NaCl final concentration for 1 hour at 4°C. Cold ethanol was added to the sample to reach a final concentration of 42% and was incubated at 4°C for 1 hour. The mixture was then centrifuged at 16,000 g for 45 minutes; both the pellet and supernatant were retained in separate micro tubes. The pellet was washed in 42% ethanol and centrifuged at 16,000 g for 45 minutes. The pellet was retained, and the second supernatant was discarded. The pH of the first supernatant collected after ethanol precipitation was reduced to 5.7 using cold 0.8 M sodium acetate (pH 4.0), and incubated at 4°C for 1 hour. This mixture was then centrifuged at 16,000 g for 45 minutes. Once again, the pellet and supernatant were retained. The two pellets were re-suspended in a triton-X lysis buffer, and the pooled supernatant with albumin was used for analytical purposes.

The re-suspended pellets were then further processed in order to remove immunoglobulins using iron nanoparticles. Briefly, protein A coated iron nanoparticles (Miltenyi, Inc.) were added to the albumin-free serum sample protein mixture and incubated at RT for one hour. A microcolumn was equilibrated with 200 µl of lysis buffer. The sample with protein A nanoparticles was then loaded into the column and allowed to elute, while the nanoparticles with attached immunoglobulins were retained within the magnetic column. The immunoglobulin-free protein sample was then subject to the TCA/Acetone precipitation for 2D-GE.

2D Gel Electrophoresis

Tri-chloro acetic acid (TCA) /Acetone Precipitation

TCA/Acetone precipitation was performed to optimize serum protein recovery. 100 µl of serum was mixed with 800 µl of ice-cold acetone and 100 µl of 100% TCA. Following incubation at −20°C for one hour and centrifugation steps, the precipitated protein pellet was dissolved in 250 µl of two-dimensional gel rehydration buffer (8 M urea, 2 % (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate) (CHAPS), 50 mM dithiothreitol (DTT) (Sigma Aldrich), and 0.2% Bio-lyte ampholyte (Bio-Rad).

Serum Protein Quantification

In order to achieve equal loading for 2D-GE the protein concentration of the samples solubilized in rehydration buffer were determined using a Bio-Rad RC/DC kit (manufacturer’s protocol was followed).

Rehydration of IPG Strip for 2D Electrophoresis

A known amount of protein was diluted to make 125 µl with rehydration buffer (8M urea, 2% CHAPS, 50mM DTT, and 0.2% Bio-lyte ampholyte). The IPG strips (Bio-Rad); pI 4 -7 were rehydrated with 125 µl sample for 11–16 hours.

First Dimensional Analysis Using Isolelectric Focusing

Isolelectric focusing (IEF) was done using a Protean IEF Cell (Bio-Rad). The IEF run was performed using the following protocol: 100 V for 3 hours, 300 V for 2 hours, 600 V for 1 hour, 1000 V for 1 hour, 2000 V for 1 hour, and 3000 V for 8 hours.

Second Dimensional Analysis by SDS-PAGE

Following the IEF, the IPG strips were equilibrated in two different buffers. The buffer solutions were comprised of 6M urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol and 2% DTT in the first equilibration buffer or 2.5% iodoacetamide instead of DTT in the second equilibration buffer. The IPG strips were equilibrated for 20 minutes in each equilibration buffer. The proteins were then further fractionated on SDS-PAGE gel and were analyzed either by silver staining or immunoblot analysis.

Immunoblotting with Anti-haptoglobin antibody

To perform an immunoblot analysis for haptoglobin, the serum samples were analyzed by 12.5% SDS-PAGE and immunoblotting was performed with anti haptoglobin antibody (Sigma). Results were visualized using chemiluminescent reagents (Perkin Elmer) and autoradiography.

Mass Spectrometry

Proteins from the silver stained gel were excised and processed for in gel digestion as described [17,18]. Briefly, gels were cut into small, uniform pieces; the gel pieces were dehydrated by acetonitrile and then rehydrated by 100 mM ammonium bicarbonate. Samples were treated with 10 mM DTT to reduce disulphide bonds followed by 50 mM iodoacetamide to block disulphides from reforming. Gel pieces were then washed with ammonium bicarbonate and dried by acetonitrile and these last two steps were repeated twice. After completely dehydrating with acetonitrile, gel pieces were suspended in 12.5 ng/µl trypsin in 50 mM ammonium bicarbonate. In-gel digestion was carried at 37°C for 10–12 hours and the peptides were extracted from the gel in 50% acetonitrile and 5% formic acid. The extract was concentrated under reduced pressure and finally desalted by C-18 containing Zip-Tip (Millipore, MA). Trypsin digested peptides were analyzed by ES-MS-MS and MALDI-TOF-TOF-MS (ABI-4800). MALDI-TOF-TOF-MS analyses were performed using the following parameters: source 1 voltage at 80 kV, source 2 voltage at 15 kV, source 1 focus at 4.3 kV, source 1 lens at 3.7 kV, Y1 deflector at 0.08 kV, grid source 1 voltage ration of 0.91, mirror 2 to mirror 1 voltage ratio of 1.7, and the mirror 2 to source 2 voltage ratio of 1.23. MS spectra were recorded in a mass range of 800–4000 Daltons. Data was collected and analyzed using the Explorer software package (ABI).

Mass Spectrometry Data Analysis

Mass spectrometry data was analyzed and interpreted using the MASCOT (ver. 2.0.04) and Protein Prospector (ver. 4.27.2 basic and ver. 5.0, UCSF) database search programs. The database search parameters were as follows: for the NCBInr database; SwissProt, tryptic digest, 2 missed cleavages, and a mass tolerance of 20–50 ppm. MS/MS data was analyzed by MASCOT.

Results

Differentially expressed haptoglobin isoforms in SCLC patient serum

To determine the differential expression of specific isoforms, we fractionated serum samples by 2D-GE and estimated quantitatively various haptoglobin isoforms by immunoblot analysis with anti haptoglobin antibody. Serum from control (pooled serum from normal individuals) and SCLC patients (eight representing stage III and Stage IV) were acetone precipitated and equal amount of proteins were analyzed. The immunoblot analysis with anti haptoglobin antibody demonstrated the presence of β, α-1 and α-2 chains in control and SCLC patients as well. Both α and β isoforms were elevated in SCLC patient samples. The streak of haptoglobin gave a very strong signal and resulted in a thick haptoglobin bands at 45 kDa (β chain) 19 kDa (α-2 chain) and 9kDa (α-1 chain) (fig. 1A and B). A comparative analysis of control and SCLC serum samples also showed a set of three spots, 5 kDa smaller than haptoglobin β chain and pIs ranging from 5 to 6 (Fig 1B, marked a,b,c,d). These haptoglobin minor isoforms were not visualized in control serum samples. The quantitative estimation of these spots indicate variation between patients and there was distinct difference between stage III and IV patient sera (table 1).

Figure 1
2D-Gel electrophoresis and immunoblot analysis
Table 1
Quantitative representation of different 40 kDa haptoglobin isoforms in SCLC patient serum.

Haptoglobin enrichment by ethanol precipitation

To further characterize low abundance minor isoforms, we first partially enriched haptoglobin by removing albumin and immunoglobulin. A combination of ethanol/sodium acetate precipitation for albumin, and protein A based removal of immunoglobulin was optimized. The haptoglobin enriched samples were analyzed by SDS-PAGE and coomasie stain. The results clearly indicate significant removal of IgG and albumin (fig. 2A). Most of the albumin was removed and collected as a separate fraction. To determine the loss of haptoglobin during fractionation, we analyzed various fractions by immunoblot analysis with an anti-haptoglobin antibody. Immunoblot analysis of post-enrichment fractions clearly demonstrated the complete absence of haptoglobin in the albumin fraction. All three major isoforms (45 kDa β, 19 kDa α-2 and 9 kDa α-1 chain of haptoglobin) were visualized (fig. 2B).

Figure 2
Haptoglobin enrichment by removal of albumin and immunoglobulins

2D-gel electrophoresis analysis of haptoglobin enriched serum

To fractionate and identify different haptoglobin isoforms, haptoglobin enriched serum samples were analyzed by two-dimensional gel electrophoresis, followed by SDS-PAGE. To visualize the proteins, the SDS-PAGE was subjected to silver staining. 2D-GE of haptoglobin enriched control serum samples showed a streaking pattern of three major proteins, albumin (64 kDa), the immunoglobulin heavy chain, and both the α and β chains of haptoglobin (fig. 3A). Several silver stain protein spots of the gel were excised and analyzed by MS for protein identification.

Figure 3
Characterization of haptoglobin isoforms by 2D-SDS-PAGE and MS

Characterization of different haptoglobin isoforms

Haptoglobin streak spots were visualized at 45 kDa, 19 kDa and 9 kDa representing β, α-2 and α-1 isoforms. The characterization of protein at 45 kDa resulted in the identification of haptoglobin isoforms and two spots with similar mass and pI were identified as apolypoprotein (fig. 3B and table 1). The pI of the β isoform ranged from 5.5 to 6.5. Four haptoglobin isoforms of α-2 with masses of approximately 19 kDa were also identified. The pI range of the α-2 isoform varied from 4.5 to 6.5 (fig. 3B). Two spots of α1 isoform with a molecular mass of 9 kDa were also identified by MS analysis in control and patient serum samples (fig. 3A and B). The protein identification was based on ES-MS/MS or MALDI-TOF-TOF-MS analysis. At least four representative peptides and at least two representative peptide MS/MS were considered minimal to confirm the identification of the proteins. The major haptoglobin isoforms were represented by several peptides and MS/MS data of most of the peptides showed significant y and b ion fragments (fig. 5).

Figure 5Figure 5
Representative MS data from a spot identified as haptoglobin

Haptoglobin isoforms differentially expressed in SCLC patient serum

In a series of experiments, we fractionated haptoglobin enriched serum samples by 2D-GE to identify and characterize differentially expressed haptoglobin isoforms. A comparative analysis of control and SCLC serum samples by 2D-GE and silver stain showed similarity however two distinct differences were striking. Higher level of haptoglobin and the presence of 40 kDa minor haptoglobin isoforms were notable. Only SCLC patient sera showed an elevated level of haptoglobin, while also containing two 40 kDa isoforms of the β chain (fig. 4A and B). Differentially expressed 40 kDa isoforms were negatively stained with silver. One of the spots was identified as haptoglobin by MS analysis however the identification of the second protein remained inconclusive. Our studies also indicate that these proteins cross reacts with anti-haptoglobin antibody (fig. 1B spot c).

Figure 4
Characterization of differentially present/expressed haptoglobin isoforms in SCLC patient samples

Discussion

To determine the differential expression of haptoglobin isoforms we analyzed control and SCLC patient serum by 2D-GE. The fractionated proteins were either characterized by silver stain and MS analysis or by immunoblot analysis with anti-haptoglobin antibody. Comparison of 2D-GE and immunoblot analysis recorded two important observations, that both the β and α haptoglobin isoforms were elevated in patient sera, and also most strikingly that there were differentially expressed β chain minor isoforms. Haptoglobin α chain heterogeneity was similar in control and SCLC patient sera. Using 2D-GE and MS-based protein characterization methods, it has been demonstrated that the mobility shift in α-1 and α-2 isoforms are due to the changes in amino acids leading to different charge states [20,21].

Acute phase proteins, such as haptoglobin has been shown to be significantly higher in the sera of patients with inflammatory diseases and cancer [2224]. Haptoglobin is synthesized in the liver, however higher levels of haptoglobin has been observed in tumor tissues [25]. This may be due to the epithelial-mesenchymal transition phenomenon, and the fact that tumor tissue demonstrates similarities with inflammatory cells, particularly activated fibroblasts [26,27]. Several studies have reported a higher level of serum haptoglobin in a variety of cancers including: ovarian, breast, small cell lung, pancreatic, liver and prostate cancers [68,15,2325,28]. The convergent themes of these studies are a higher circulatory level of serum haptoglobin and an altered glycosylation status of the β chain. However, there is no consensus on the specificity of differential expression of haptoglobin isoforms or specific glycans.

Higher levels of haptoglobin may be attributed to higher protein levels and/or increased glycosylation of the β isoform in particular. Saldova et. al have determined the correlation between cancer progression and isoform glycosylation. They have concluded that changes in glycoforms in haptoglobin β chain, α1-acid glycoprotein and α1-antichymotrypsin leads to changes in the total serum glycome of patients with advanced ovarian cancer. These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis × (SLe ×) [29]. Our observation of higher levels of the β isoform of haptoglobin further extends these findings.

The other significant difference between control and SCLC patient sera was the differential expression of minor isoforms of the β chain. There were two different sets of spots, several minor isoforms 1–2 kDa below the 45 kDa β isoform (will be referred to as the 44 kDa isoform) with basic pIs between 5.5 and 7.0. The other set with 3–5 spots approximately 5 kDa smaller than the 45 kDa β isoform was observed only in patient samples (referred to as the 40 kDa isoforms) (fig. 1). The pIs of these isoforms were acidic, between 4.5 and 6.0. The 44 kDa minor β haptoglobin isoforms appear in doublet and have also been observed in alcoholic and cirrhotic patients [30]. Gravel et. al has attributed these changes to altered glycosylation. They have demonstrated the loss of terminal sialic acid, the galactose residue and the N-acetylglucosamine residue which are located at the penultimate and antepenultimate position of the glycan chains, respectively. However, He et al concluded that sialic acid content of major isoforms determine their separation by isoelectric focusing, but the analysis of doublets of minor isoforms indicated similar glycan structure, thus the heterogeneity in minor isoforms was due to modifications distinct from N-glycan structure [11]. In SCLC patients serum, we have also observed several 43–44 kDa minor isoforms with altered mobility towards basic pIs. Micro-characterization of these isoforms will be important to determine their correlation to SCLC disease progression.

The second haptoglobin minor isoforms were 4–5 kDa smaller than the 45 kDa β chain and maintain acidic pIs (4.5 to 5.5). This haptoglobin isoform has not yet been reported in any other cancer or inflammatory disease. The relative abundance of these isoforms are very low and to further characterize these isoforms we enriched control and SCLC patients serum samples by removing albumin and immunoglobulins. Albumin was removed by ethanol precipitation as described by Colantonio et. al [16]. In their procedure, removal of highly abundant proteins such as albumin is coupled to powerful protein separation methods in order to increase sample loads, thus facilitating detection and identification of low abundance proteins. The haptoglobin enriched serum fractions from control and SCLC patients were analyzed by 2D-GE and silver staining. Two 40 kDa protein spots were visible only in SCLC patient sera. These spots were negatively stained indicating the acidic nature of the proteins [31]. One of the spots was identified as haptoglobin, while the other was identified as apolypoprotein. The other two minor haptoglobins identified by immunoblotting were not observed in silver stain gels, possibly due to the lack of comparative sensitivity of silver staining.

Hakomori and colleagues have characterized serum haptoglobin in their effort to determine the correlation between glycosylation status and prostate cancer progression [8]. They purified haptoglobin from control, benign and prostate cancer patients and characterized the glycans by mass spectrometry. They concluded that levels of haptoglobin are enhanced in sera of prostate cancer patients, and the N-glycans attached to a defined region of its β chain are characterized by enhanced branching as well as antenna fucosylation [8]. They further characterized their putative glycan structure, as well as determining their relative abundance. Most of the glycans except three were increased in patient sera. They have demonstrated the reduction in the level of these three glycans in patient sera. The mass of these glycans vary from 5 to 6 kDa. We are temped to draw a parallel conclusion and characterize the 40 kDa minor haptoglobin isoform in our studies as reduction in certain glycans in SCLC patient serum as well. However, deletion of these glycans will significantly change the pI to basic, thus the loss of a glycan structure does not explain the differential expression of these minor β haptoglobin isoforms. These isoforms are recognized by anti-haptoglobin antibody and by mass spectrometry. The anti-haptoglobin antibodies are highly specific as they have very little or no cross reactivity with the most abundant proteins, i.e. albumin. Also, we have characterized at least one minor isoform by MS analysis. Taken together, these differentially expressed proteins represent haptoglobin isoforms. However, we have not yet fully characterized these isoforms. Currently we are purifying haptoglobin from control and SCLC patient sera to further characterize the 40 kDa minor haptoglobin isoforms.

Acknowledgement

We are grateful to Paul Morrison for providing us the resources at Blais Proteomics Center at the Dana-Farber Cancer Institute. This work was supported by a pilot grant from the Department of Medicine to Ajit Bharti and . 5R01CA100750-06 from National Cancer Institute to Ravi Salgia.

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar–Apr;56(2):106–130. [PubMed]
2. Gail MH, Muenz L, McIntire KR, et al. Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. J Natl Cancer Inst. 1988 Mar 16;80(2):97–101. [PubMed]
3. McCarthy NJ, Swain SM. Tumor markers: should we or shouldn't we? Cancer J. 2001 May–Jun;7(3):175–177. [PubMed]
4. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002 Sep;122(3):1037–1057. [PubMed]
5. Ma PC, Blaszkowsky L, Bharti A, et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2003 Jan–Feb;23(1A):49–62. [PubMed]
6. Ang IL, Poon TC, Lai PB, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res. 2006 Oct;5(10):2691–2700. [PubMed]
7. Okuyama N, Ide Y, Nakano M, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer. 2006 Jun 1;118(11):2803–2808. [PubMed]
8. Fujimura T, Shinohara Y, Tissot B, et al. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer. 2008 Jan 1;122(1):39–49. [PubMed]
9. Andersen MN, Mouritzen CV, Gabrielli ER. Mechanisms of plasma hemoglobin clearance after acute hemolysis in dogs: serum haptoglobin levels and selective deposition in liver and kidney. Ann Surg. 1966 Nov;164(5):905–912. [PubMed]
10. Langlois M, Delanghe J, De Buyzere M. Relation between serum IgA concentration and haptoglobin type. Clin Chem. 1996 Oct;42(10):1722–1723. [PubMed]
11. He Z, Aristoteli LP, Kritharides L, Garner B. HPLC analysis of discrete haptoglobin isoform N-linked oligosaccharides following 2D-PAGE isolation. Biochem Biophys Res Commun. 2006 May 5;343(2):496–503. [PubMed]
12. Kurosky A, Barnett DR, Lee TH, et al. Covalent structure of human haptoglobin: a serine protease homolog. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3388–3392. [PubMed]
13. Maeda N, McEvoy SM, Harris HF, Huisman TH, Smithies O. Polymorphisms in the human haptoglobin gene cluster: chromosomes with multiple haptoglobin-related (Hpr) genes. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7395–7399. [PubMed]
14. Patzelt D, Geserick G, Schroder H. The genetic haptoglobin polymorphism: relevance of paternity assessment. Electrophoresis. 1988 Aug;9(8):393–397. [PubMed]
15. Bharti A, Ma PC, Maulik G, et al. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar–Apr;24(2C):1031–1038. [PubMed]
16. Colantonio DA, Dunkinson C, Bovenkamp DE, Van Eyk JE. Effective removal of albumin from serum. Proteomics. 2005 Oct;5(15):3831–3835. [PubMed]
17. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis. Anal Biochem. 1992 May 15;203(1):173–179. [PubMed]
18. Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source. Anal Chem. 1996 Jan 1;68(1):1–8. [PubMed]
19. Matuszek MA, Aristoteli LP, Bannon PG, et al. Haptoglobin elutes from human atherosclerotic coronary arteries--a potential marker of arterial pathology. Atherosclerosis. 2003 Jun;168(2):389–396. [PubMed]
20. Connell GE, Dixon GH, Smithies O. Subdivision of the three common haptoglobin types based on 'hidden' diffrences. Nature. 1962 Feb 3;193:505–506. [PubMed]
21. Brune JL, Yang F, Barnett DR, Bowman BH. Evolution of haptoglobin: comparison of complementary DNA encoding Hp alpha 1S and Hp alpha 2FS. Nucleic Acids Res. 1984 Jun 11;12(11):4531–4538. [PMC free article] [PubMed]
22. Turner GA. Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol. 1995;376:231–238. [PubMed]
23. Thompson S, Turner GA. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera. Br J Cancer. 1987 Nov;56(5):605–610. [PMC free article] [PubMed]
24. Thompson S, Dargan E, Griffiths ID, Kelly CA, Turner GA. The glycosylation of haptoglobin in rheumatoid arthritis. Clin Chim Acta. 1993 Oct 29;220(1):107–114. [PubMed]
25. Ahmed N, Barker G, Oliva KT, et al. Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer. 2004 Jul 5;91(1):129–140. [PMC free article] [PubMed]
26. Hey E. Hyperglycaemia and the very preterm baby. Semin Fetal Neonatal Med. 2005 Aug;10(4):377–387. [PubMed]
27. Lee JW, Kim HS. Endogenous retrovirus HERV-I LTR family in primates: sequences, phylogeny, and evolution. Arch Virol. 2006 Aug;151(8):1651–1658. [PubMed]
28. Kossowska B, Ferens-Sieczkowska M, Gancarz R, Passowicz-Muszynska E, Jankowska R. Fucosylation of serum glycoproteins in lung cancer patients. Clin Chem Lab Med. 2005;43(4):361–369. [PubMed]
29. Tabares G, Radcliffe CM, Barrabes S, et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology. 2006 Feb;16(2):132–145. [PubMed]
30. Gravel P, Walzer C, Aubry C, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun. 1996 Mar 7;220(1):78–85. [PubMed]
31. Goldberg HA, Warner KJ. The staining of acidic proteins on polyacrylamide gels: enhanced sensitivity and stability of "Stains-all" staining in combination with silver nitrate. Anal Biochem. 1997 Sep 5;251(2):227–233. [PubMed]
32. Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev. 2007 May–Jun;26(3):451–466. [PubMed]